CD30 , conosciuto anche come TNFRSF8 , è una proteina di membrana cellulare appartenente alla famiglia dei recettori per i fattori di necrosi tumorale e marker tumorali .
Pattern di espressione del gene TNFRSF8 Questo recettore è espresso mediante attivazione, dalle cellule T e B. TRAF2 e TRAF5 possono interagire con questo recettore, e mediare la trasduzione del segnale che porta all'attivazione di NF-κB. Si tratta di un regolatore che promuove l'apoptosi , ed è in grado di limitare il potenziale proliferativo delle cellule CD8 T e quindi proteggere il corpo contro l'autoimmunità . Due varianti di trascrizione tramite splicing alternativo di questo gene che codificano due isoforme della proteina.[ 1]
CD30 è associato al linfoma anaplastico a grandi cellule. Viene espresso nel carcinoma embrionale, ma non nel seminoma ed è quindi un indicatore utile per distinguere tra questi tumori delle cellule germinali.[ 2] [ 3]
Interazioni
CD30 effettua interazioni proteina-proteina con: TRAF5 ,[ 4] TRAF1 ,[ 5] TRAF2 .[ 4] [ 5] TRAF3 .[ 5]
Note
^ Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily, member 8 ncbi.nlm.nih.gov . ^ (ZH [Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors] , in Zhonghua Bing Li Xue Za Zhi , vol. 34, n. 11, 2005, pp. 711–5, PMID 16536313 . ^ Gorczyca W, Tsang P, Liu Z, et al. , CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis , in Int. J. Oncol. , vol. 22, n. 2, febbraio 2003, pp. 319–24, PMID 12527929 . ^ a b S Aizawa, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T, Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation J. Biol. Chem. , vol. 272, n. 4, Jan. 1997, pp. 2042–5, DOI :10.1074/jbc.272.4.2042 , PMID 8999898 . ^ a b c S Ansieau, Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K, Harada J, Dougall B, Hübinger G, Kieff E, Herrmann F, Leutz A, Gruss H J, Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation Proc. Natl. Acad. Sci. U.S.A. DOI :10.1073/pnas.93.24.14053 , PMC 19493 , PMID 8943059 .
Bibliografia
Schneider C, Hübinger G, Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family. Leuk. Lymphoma , vol. 43, n. 7, 2003, pp. 1355–66, DOI :10.1080/10428190290033288 , PMID 12389614 . Horie R, Higashihara M, Watanabe T, Hodgkin's lymphoma and CD30 signal transduction. Int. J. Hematol. , vol. 77, n. 1, 2003, pp. 37–47, DOI :10.1007/BF02982601 , PMID 12568298 . Tarkowski M, Expression and a role of CD30 in regulation of T-cell activity. Curr. Opin. Hematol. , vol. 10, n. 4, 2004, pp. 267–71, DOI :10.1097/00062752-200307000-00003 , PMID 12799531 . Granados S, Hwang ST, Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases. J. Invest. Dermatol. , vol. 122, n. 6, 2004, pp. 1345–7, DOI :10.1111/j.0022-202X.2004.22616.x , PMID 15175022 . Dürkop H, Latza U, Hummel M, et al. , Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell , vol. 68, n. 3, 1992, pp. 421–7, DOI :10.1016/0092-8674(92)90180-K , PMID 1310894 . Fonatsch C, Latza U, Dürkop H, et al. , Assignment of the human CD30 (Ki-1) gene to 1p36. Genomics , vol. 14, n. 3, 1992, pp. 825–6, DOI :10.1016/S0888-7543(05)80203-4 , PMID 1330892 . Josimovic-Alasevic O, Dürkop H, Schwarting R, et al. , Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo . I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur. J. Immunol. , vol. 19, n. 1, 1989, pp. 157–62, DOI :10.1002/eji.1830190125 , PMID 2537734 . Stein H, Gerdes J, Schwab U, et al. , Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int. J. Cancer , vol. 30, n. 4, 1983, pp. 445–59, DOI :10.1002/ijc.2910300411 , PMID 6754630 . Jung W, Krueger S, Renner C, et al. , Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources. Mol. Immunol. , vol. 31, n. 17, 1995, pp. 1329–34, DOI :10.1016/0161-5890(94)90051-5 , PMID 7527901 . Shiota M, Fujimoto J, Semba T, et al. , Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. , in Oncogene , vol. 9, n. 6, 1994, pp. 1567–74, PMID 8183550 . Lee SY, Park CG, Choi Y, T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J. Exp. Med. , vol. 183, n. 2, 1996, pp. 669–74, DOI :10.1084/jem.183.2.669 , PMC 2192463 , PMID 8627180 . Gedrich RW, Gilfillan MC, Duckett CS, et al. , CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J. Biol. Chem. , vol. 271, n. 22, 1996, pp. 12852–8, DOI :10.1074/jbc.271.22.12852 , PMID 8662842 . Horie R, Ito K, Tatewaki M, et al. , A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages. , in Blood , vol. 88, n. 7, 1996, pp. 2422–32, PMID 8839832 . Ansieau S, Scheffrahn I, Mosialos G, et al. , Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc. Natl. Acad. Sci. U.S.A. , vol. 93, n. 24, 1997, pp. 14053–8, DOI :10.1073/pnas.93.24.14053 , PMC 19493 , PMID 8943059 . Aizawa S, Nakano H, Ishida T, et al. , Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J. Biol. Chem. , vol. 272, n. 4, 1997, pp. 2042–5, DOI :10.1074/jbc.272.4.2042 , PMID 8999898 . Lee SY, Lee SY, Choi Y, TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. J. Exp. Med. , vol. 185, n. 7, 1997, pp. 1275–85, DOI :10.1084/jem.185.7.1275 , PMC 2196258 , PMID 9104814 . Boucher LM, Marengère LE, Lu Y, et al. , Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. Biochem. Biophys. Res. Commun. , vol. 233, n. 3, 1997, pp. 592–600, DOI :10.1006/bbrc.1997.6509 , PMID 9168896 . Duckett CS, Thompson CB, CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev. , vol. 11, n. 21, 1997, pp. 2810–21, DOI :10.1101/gad.11.21.2810 , PMC 316646 , PMID 9353251 . Mizushima S, Fujita M, Ishida T, et al. , Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5). Gene , vol. 207, n. 2, 1998, pp. 135–40, DOI :10.1016/S0378-1119(97)00616-1 , PMID 9511754 . Kurts C, Carbone FR, Krummel MF, et al. , Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature , vol. 398, n. 6725, 1999, pp. 341–4, DOI :10.1038/18692 , PMID 10192335 .
Collegamenti esterni
Information related to CD30
